|
Novonesis, a global biosolutions leader, will demonstrate how biosolutions can support more efficient food production while enhancing taste, texture, and nutritional quality that can provide benefits to Korean consumers.
SEOUL, South Korea, June 8, 2026 /PRNewswire/ -- As Korean food producers navigate rising input costs, margin pressure, and raw material price volatility, biosolutions — microbes, enzymes, and proteins — offer new opportunities to improve operational efficiency and meet evolving consumer demands.
At this year's Seoul Food & Hotel, Korea's largest food and hospitality trade show, global biosolutions leader Novonesis is demonstrating how biosolutions can help address key challenges that the Korean food industry is facing.
Biosolutions can help food producers enhance taste and texture, create cleaner ingredient labels, reduce waste, and improve production efficiency. Across applications such as yogurt, cheese, meat, baked goods, and plant-based products, producers can achieve more with less while maintaining high standards for taste, texture, and food safety.
"Korean consumers are both health and quality conscious, and more aware of labels than ever. Food producers are facing cost volatility and pressure to perform more efficiently. Seoul Food & Hotel 2026 is a great opportunity for us to connect with producers and show firsthand how biosolutions can help them navigate both." says Yo Miyashita, Head of Food & Beverage Biosolutions Japan and Korea.
Visitors at the Novonesis booth can engage with technical specialists and account managers, and taste yogurt and fish cake samples for themselves, to explore how our lactic acid bacterial cultures and enzymes can be customized and tailored across a wide range of foods to enhance taste, texture, and shelf life.
At the event, Novonesis will also introduce a new transglutaminase solution to the Korean market. This enzyme helps improve texture, elasticity, and protein binding across applications such as meat, seafood, and plant-based products, helping producers achieve more consistent quality, improve slicing yield, and reduce production inefficiency.
Novonesis will participate in Seoul Food & Hotel 2026 from 9–12 June at booth number 2F603. The company will showcase solutions across a wide range of industries not limited to food areas. Novonesis' Human Health Biosolutions offer probiotics, enzymes, and specialized proteins to support evolving health and nutritional needs and Planetary Health Biosolutions help industrial players reduce reliance on fossil-based chemicals and drive higher yields from fewer resources.
Ancient practice, modern scale
For thousands of years, fermentation has been at the heart of food culture, used to preserve, enhance flavor, and improve nutrition. Korea knows this from history: kimchi, doenjang, and ganjang are all products of biology doing what it has always done, naturally.
That biological heritage runs deep in Korean everyday life. Koreans are among the world's most enthusiastic consumers of enzymes and probiotic supplements, taken daily to support digestion and gut health.
Novonesis takes the same biological approach to industrial scale, applying it across food and biotics solutions to improve everyday food and support healthier living.
About Novonesis
Novonesis is leading the era of biosolutions.
By leveraging the power of microbiology with science, we transform the way the world produces, consumes and lives. In more than 30 industries around the world, our biosolutions are already creating value for thousands of customers and benefiting the planet.
Our 11,000 people worldwide work closely with our partners and customers to transform business with biology.
Novonesis, a global biosolutions leader, will demonstrate how biosolutions can support more efficient food production while enhancing taste, texture, and nutritional quality that can provide benefits to Korean consumers.
SEOUL, South Korea, June 8, 2026 /PRNewswire/ -- As Korean food producers navigate rising input costs, margin pressure, and raw material price volatility, biosolutions — microbes, enzymes, and proteins — offer new opportunities to improve operational efficiency and meet evolving consumer demands.
At this year's Seoul Food & Hotel, Korea's largest food and hospitality trade show, global biosolutions leader Novonesis is demonstrating how biosolutions can help address key challenges that the Korean food industry is facing.
Biosolutions can help food producers enhance taste and texture, create cleaner ingredient labels, reduce waste, and improve production efficiency. Across applications such as yogurt, cheese, meat, baked goods, and plant-based products, producers can achieve more with less while maintaining high standards for taste, texture, and food safety.
"Korean consumers are both health and quality conscious, and more aware of labels than ever. Food producers are facing cost volatility and pressure to perform more efficiently. Seoul Food & Hotel 2026 is a great opportunity for us to connect with producers and show firsthand how biosolutions can help them navigate both." says Yo Miyashita, Head of Food & Beverage Biosolutions Japan and Korea.
Visitors at the Novonesis booth can engage with technical specialists and account managers, and taste yogurt and fish cake samples for themselves, to explore how our lactic acid bacterial cultures and enzymes can be customized and tailored across a wide range of foods to enhance taste, texture, and shelf life.
At the event, Novonesis will also introduce a new transglutaminase solution to the Korean market. This enzyme helps improve texture, elasticity, and protein binding across applications such as meat, seafood, and plant-based products, helping producers achieve more consistent quality, improve slicing yield, and reduce production inefficiency.
Novonesis will participate in Seoul Food & Hotel 2026 from 9–12 June at booth number 2F603. The company will showcase solutions across a wide range of industries not limited to food areas. Novonesis' Human Health Biosolutions offer probiotics, enzymes, and specialized proteins to support evolving health and nutritional needs and Planetary Health Biosolutions help industrial players reduce reliance on fossil-based chemicals and drive higher yields from fewer resources.
Ancient practice, modern scale
For thousands of years, fermentation has been at the heart of food culture, used to preserve, enhance flavor, and improve nutrition. Korea knows this from history: kimchi, doenjang, and ganjang are all products of biology doing what it has always done, naturally.
That biological heritage runs deep in Korean everyday life. Koreans are among the world's most enthusiastic consumers of enzymes and probiotic supplements, taken daily to support digestion and gut health.
Novonesis takes the same biological approach to industrial scale, applying it across food and biotics solutions to improve everyday food and support healthier living.
About Novonesis
Novonesis is leading the era of biosolutions.
By leveraging the power of microbiology with science, we transform the way the world produces, consumes and lives. In more than 30 industries around the world, our biosolutions are already creating value for thousands of customers and benefiting the planet.
Our 11,000 people worldwide work closely with our partners and customers to transform business with biology.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Novonesis showcases biosolutions for Korean food producers at Seoul Food & Hotel 2026
|
SAN DIEGO, June 8, 2026 /PRNewswire/ -- Sapu Bioscience LLC announced the expansion of its Phase 1b clinical development program for Sapu003 (Everolimus for Injection) and the appointment of Global Clinical Trials (GCT) as the lead contract research organization supporting international execution of Study SP-03-B101.
The announcement follows recent regulatory approvals supporting the study expansion and CRO transition and represents an important milestone in the evolution of the Sapu003 clinical program from its initial Australian clinical footprint toward a broader multinational development strategy.
GCT was selected following a competitive evaluation process that assessed international oncology expertise, regulatory capabilities, operational execution, clinical quality systems, and global logistics infrastructure. Following its appointment, GCT successfully completed key regulatory submissions ahead of schedule and has initiated clinical operations, regulatory coordination, site activation activities, investigational product logistics, and study management functions.
The appointment supports the expansion of the SP-03-B101 study beyond Australia into Europe and international territories and represents an important step in establishing the clinical, operational, and regulatory infrastructure necessary to support future multinational Phase 3 development. By building an international clinical network early in development, Sapu Nano aims to position Sapu003 for efficient advancement into global registrational studies following successful completion of ongoing clinical evaluation.
SP-03-B101 is an open-label Phase 1b dose-escalation study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of Sapu003 in patients with advanced mTOR-sensitive solid tumors.
"Sapu003 has progressed from concept through formulation development, manufacturing, regulatory approval, and clinical evaluation in a remarkably short period of time," said Dr. Vuong Trieu, Chief Executive Officer. "The expansion of the program beyond Australia and the appointment of GCT provide the international infrastructure necessary to support continued clinical development. We believe these milestones position Sapu003 for broader global evaluation and potentially future registrational studies while expanding access for patients with advanced cancers."
Sapu003 is a proprietary intravenous formulation of everolimus developed using Sapu Nano's Deciparticle™ platform technology. The program is designed to address limitations associated with oral everolimus administration, including variable absorption, food effects, and first-pass metabolism, while providing more predictable systemic drug exposure through intravenous delivery.
The Company expects the expanded international footprint and integrated clinical operations platform established through GCT to support continued enrollment, future site expansion, and long-term global development objectives for the Sapu003 program.
About Sapu Nano's Deciparticle™
Sapu Nano's Deciparticle™ is a proprietary nanomedicine platform designed to formulate highly water-insoluble therapeutics into ultra-small nanoparticles for intravenous administration. The platform utilizes amphiphilic polymer architectures intended to improve aqueous compatibility, stability, manufacturability, and translational flexibility across multiple therapeutic classes.
About Sapu Nano
Sapu Nano is a biotechnology company developing next-generation nanomedicine platforms to improve drug delivery, enhance therapeutic index, and unlock new clinical potential for established and novel therapeutics, with a primary focus in oncology. For more information, visit www.sapunano.com.
Media Contact
Sapu Nano
10801 Thornmint Rd., Suite 150
San Diego, CA 92127
Phone: (858) 521-8037
Email: info@sapunano.com
SAN DIEGO, June 8, 2026 /PRNewswire/ -- Sapu Bioscience LLC announced the expansion of its Phase 1b clinical development program for Sapu003 (Everolimus for Injection) and the appointment of Global Clinical Trials (GCT) as the lead contract research organization supporting international execution of Study SP-03-B101.
The announcement follows recent regulatory approvals supporting the study expansion and CRO transition and represents an important milestone in the evolution of the Sapu003 clinical program from its initial Australian clinical footprint toward a broader multinational development strategy.
GCT was selected following a competitive evaluation process that assessed international oncology expertise, regulatory capabilities, operational execution, clinical quality systems, and global logistics infrastructure. Following its appointment, GCT successfully completed key regulatory submissions ahead of schedule and has initiated clinical operations, regulatory coordination, site activation activities, investigational product logistics, and study management functions.
The appointment supports the expansion of the SP-03-B101 study beyond Australia into Europe and international territories and represents an important step in establishing the clinical, operational, and regulatory infrastructure necessary to support future multinational Phase 3 development. By building an international clinical network early in development, Sapu Nano aims to position Sapu003 for efficient advancement into global registrational studies following successful completion of ongoing clinical evaluation.
SP-03-B101 is an open-label Phase 1b dose-escalation study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of Sapu003 in patients with advanced mTOR-sensitive solid tumors.
"Sapu003 has progressed from concept through formulation development, manufacturing, regulatory approval, and clinical evaluation in a remarkably short period of time," said Dr. Vuong Trieu, Chief Executive Officer. "The expansion of the program beyond Australia and the appointment of GCT provide the international infrastructure necessary to support continued clinical development. We believe these milestones position Sapu003 for broader global evaluation and potentially future registrational studies while expanding access for patients with advanced cancers."
Sapu003 is a proprietary intravenous formulation of everolimus developed using Sapu Nano's Deciparticle™ platform technology. The program is designed to address limitations associated with oral everolimus administration, including variable absorption, food effects, and first-pass metabolism, while providing more predictable systemic drug exposure through intravenous delivery.
The Company expects the expanded international footprint and integrated clinical operations platform established through GCT to support continued enrollment, future site expansion, and long-term global development objectives for the Sapu003 program.
About Sapu Nano's Deciparticle™
Sapu Nano's Deciparticle™ is a proprietary nanomedicine platform designed to formulate highly water-insoluble therapeutics into ultra-small nanoparticles for intravenous administration. The platform utilizes amphiphilic polymer architectures intended to improve aqueous compatibility, stability, manufacturability, and translational flexibility across multiple therapeutic classes.
About Sapu Nano
Sapu Nano is a biotechnology company developing next-generation nanomedicine platforms to improve drug delivery, enhance therapeutic index, and unlock new clinical potential for established and novel therapeutics, with a primary focus in oncology. For more information, visit www.sapunano.com.
Media Contact
Sapu Nano
10801 Thornmint Rd., Suite 150
San Diego, CA 92127
Phone: (858) 521-8037
Email: info@sapunano.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Sapu Nano Expands International Development of Sapu003 and Appoints Global Clinical Trials (GCT) as Lead CRO for Phase 1b Program
